NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for chronic liver and related metabolic diseases.  NeuroBo has clinical programs targeting non-alcoholic steatohepatitis (NASH), obesity, and Type 2 diabetes.

Our strategic partner and the largest shareholder, Dong-A ST Co. Ltd., is part of Dong-A Socio Group of companies established in 1932 and based in South Korea. We have the full support of Dong-A ST’s R&D resources and Research Center which was established in 1977 as the first pharmaceutical research center in Korea. We are strengthening our strategic partnership.

DA-1241 is a once-daily, oral drug currently in early clinical development as a potential treatment for NASH and Type 2 diabetes.

DA-1726 is a drug candidate for once-a-week injection as a potential treatment for obesity, Type 2 diabetes and NASH and is pending IND submission.